AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

TELIX PHARMACEUTICALS LTD

25.310

-0.250-0.98%

Volume:635.79K

Turnover:16.18M

Market Cap:8.55B

PE:175.03

High:25.700

Open:25.500

Low:25.200

Close:25.560

Loading ...

Overview Company News Filings

Telix Pharmaceuticals' Revenue Surges 46% in Q4; Full-Year Revenue Beats Guidance

MT Newswires Live

Best ASX 200 shares vs. best suburbs for property investment in 2024

Telix Pharmaceuticals to Acquire Assets of ImaginAb for $45 Million

MT Newswires Live

ASX Stocks Trading Below Estimated Value January 2025

Simply Wall St.

BRIEF-Telix Exceeds FY24 Guidance With $142 Mln Q4 Rev

BRIEF-Telix Pharmaceuticals Posts Q4 Unaudited Revenue $142 Mln

Telix Exceeds FY24 Guidance With US$142M Q4 Revenue

THOMSON REUTERS

Press Release: Telix Exceeds FY24 Guidance with US$142M Q4 Revenue

Telix Pharmaceuticals Ltd - Q4 2024 Unaudited Revenue of US$142 Mln, up 46%

THOMSON REUTERS

ASX Market Update: Bourse falls as Bain Capital ups the ante in fight for Insignia Financial | January 13, 2025

The Market Herald

BRIEF-Telix Pharmaceuticals To Acquire Next-Gen Therapeutics And Biologics Platform

Telix to Acquire ImaginAb's Drug Candidate Pipeline, Biologics Technology Platform for $45 Million

MT Newswires Live

Up 120% in a year, ASX 200 healthcare stock dips on US acquisition

Telix to Acquire Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform

THOMSON REUTERS

Telix takes on ‘next-gen’ cancer drug candidates through $372m asset buy

The Market Herald

Telix Pharmaceuticals Ltd - Tlx to Acquire Next-Gen Therapeutics and Biologics Platform

THOMSON REUTERS

Telix Pharmaceuticals Ltd - Purchase Price for Transaction Is US$45 Mln

THOMSON REUTERS

Here's how the ASX 200 market sectors stacked up last week

16 ASX shares that doubled in value last year

Shares vs. property: Which investment delivered the best capital growth in 2024?

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/TLX.AU/news?page=10"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TLX.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TLX.AU\",,,,,undefined,":{"symbol":"TLX.AU","market":"AU","secType":"STK","nameCN":"TELIX PHARMACEUTICALS LTD","latestPrice":25.31,"timestamp":1747280073882,"preClose":25.56,"halted":0,"volume":635790,"delay":0,"nameEN":"TELIX PHARMACEUTICALS LTD","floatShares":274998041,"shares":337969665,"eps":0.1446,"marketStatus":"Trading","change":-0.25,"latestTime":"05-15 13:34:43 AEST","open":25.5,"high":25.7,"low":25.2,"amount":16183804,"amplitude":0.019562,"askPrice":25.33,"askSize":83,"bidPrice":25.31,"bidSize":855,"shortable":3,"etf":0,"ttmEps":0.1446,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1747288800000},"marketStatusCode":2,"adr":0,"exchange":"ASX","adjPreClose":25.56,"openAndCloseTimeList":[[1747267200000,1747288800000]],"volumeRatio":0.462355,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TLX.AU\",,,,,undefined,":{"symbol":"TLX.AU","floatShares":274998041,"roa":"5.33%","roe":"13.92%","lyrEps":0.150709,"volumeRatio":0.462355,"shares":337969665,"dividePrice":0,"high":25.7,"amplitude":0.019562,"preClose":25.56,"low":25.2,"week52Low":14.42,"pbRate":"15.05","psRate":"10.92","week52High":31.97,"institutionHeld":0,"latestPrice":25.31,"committee":0.823028,"eps":0.1446,"divideRate":0,"volume":635790,"delay":0,"ttmEps":0.1446,"open":25.5,"prevYearClose":24.61,"prevWeekClose":26.8,"prevMonthClose":27.13,"prevQuarterClose":26.52,"fiveDayClose":26.62,"twentyDayClose":26.36,"sixtyDayClose":27.37},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TLX.AU\",pageSize:20,pageCount:10,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2503556623","title":"Telix Pharmaceuticals' Revenue Surges 46% in Q4; Full-Year Revenue Beats Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2503556623","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503556623?lang=en_us&edition=fundamental","pubTime":"2025-01-14 05:43","pubTimestamp":1736804582,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals (ASX:TLX) reported unaudited revenue of roughly $142 million for the fourth quarter of 2024, an increase of 46% from the year-earlier period's $97 million, according to a Monday ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TLX","TLX.AU"],"gpt_icon":0},{"id":"2503532068","title":"Best ASX 200 shares vs. best suburbs for property investment in 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2503532068","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503532068?lang=en_us&edition=fundamental","pubTime":"2025-01-14 03:30","pubTimestamp":1736796600,"startTime":"0","endTime":"0","summary":"Were you invested in ASX 200 shares vs. property last year?","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/01/14/best-asx-200-shares-vs-best-suburbs-for-property-investment-in-2024/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7503","BK7084","BK7093","XKO.AU","PME.AU","ZIP.AU","BK7054","BK7016","BK7067","XAO.AU","PNI.AU","360.AU","BK7062","SIG.AU","CDA.AU","HUB.AU","TNE.AU","CU6.AU","BK7094","BK7096","TLX.AU","XJO.AU","BK7103"],"gpt_icon":0},{"id":"2503796327","title":"Telix Pharmaceuticals to Acquire Assets of ImaginAb for $45 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2503796327","media":"MT Newswires Live","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503796327?lang=en_us&edition=fundamental","pubTime":"2025-01-13 16:47","pubTimestamp":1736758053,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals  said Sunday it has agreed to purchase a pipeline of drug candidates, a proprietary biologics technology platform, and a protein engineering and discovery research facility from ImaginAb for $45 million in cash and stock plus future milestone, royalty, and sublicense payments.Under the deal, Telix said it will pay $10 million in cash and $31 million in stock at closing and $4 million in stock after 15 months.In addition, it will pay up to $185 million in payments upon achievement of certain development and commercial milestones, as well as royalties and sublicense fees in the low single digits, the company said,The early-stage cancer drug candidates acquired use \"small engineered antibody formats that enable highly specific cancer targeting, combined with fast tumor uptake and blood clearance,\" the company said.The acquisition also includes a research facility in California already staffed by a team of experts, the company said.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TLX.AU","TLX","BK7067","BK4139"],"gpt_icon":0},{"id":"2503232439","title":"ASX Stocks Trading Below Estimated Value January 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2503232439","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503232439?lang=en_us&edition=fundamental","pubTime":"2025-01-13 16:02","pubTimestamp":1736755336,"startTime":"0","endTime":"0","summary":"Top 10 Undervalued Stocks Based On Cash Flows In Australia. Lovisa Holdings is currently trading at A$25.54, slightly below its estimated fair value of A$28.54, suggesting it may be undervalued based on cash flows. The company's revenue is projected to grow at 12% annually, outpacing the broader Australian market's 6% growth rate. However, its dividend yield of 3.41% is not well covered by earnings. Earnings are expected to grow at 15.16% per year, surpassing the market average of 12.5%.Overview: SiteMinder Limited develops, markets, and sells an online guest acquisition platform and commerce solutions for accommodation providers both in Australia and internationally, with a market cap of A$1.61 billion.SiteMinder, trading at A$5.66, is undervalued relative to its fair value of A$6.95 and below analyst price targets with a projected 23.5% rise. The company has demonstrated robust earnings growth of 23.5% annually over the past five years and is expected to become profitable within thre","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/asx-stocks-trading-below-estimated-080216568.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["LOV.AU","XKO.AU","BK7062","BK7090","SFR.AU","BK7104","GMD.AU","BK7128","BK7064","BK7503","BK7067","XJO.AU","BK7015","TLX.AU","BK7506","VAU.AU","MLG.AU","ABB.AU","MIL.AU","SDR.AU","BK7095","BK7110","BK7043","BK7507","BK7016","XAO.AU","ALX.AU","DTL.AU","RPL.AU","MP1.AU","BK7061"],"gpt_icon":0},{"id":"2503296013","title":"BRIEF-Telix Exceeds FY24 Guidance With $142 Mln Q4 Rev","url":"https://stock-news.laohu8.com/highlight/detail?id=2503296013","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503296013?lang=en_us&edition=fundamental","pubTime":"2025-01-13 15:41","pubTimestamp":1736754081,"startTime":"0","endTime":"0","summary":"BRIEF-Telix Exceeds FY24 Guidance With $142 Mln Q4 RevJan 13 (Reuters) - Telix Pharmaceuticals Ltd TLX.AX:TELIX EXCEEDS FY24 GUIDANCE WITH US$142M Q4 REVENUESource text: ID:nGNX70xsPjFurther company coverage: TLX.AX ((Reuters.Briefs@thomsonreuters.com))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250113:nTUA7DGVTH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLX.AU","BK7067"],"gpt_icon":0},{"id":"2503260373","title":"BRIEF-Telix Pharmaceuticals Posts Q4 Unaudited Revenue $142 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2503260373","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503260373?lang=en_us&edition=fundamental","pubTime":"2025-01-13 15:36","pubTimestamp":1736753811,"startTime":"0","endTime":"0","summary":"BRIEF-Telix Pharmaceuticals Posts Q4 Unaudited Revenue $142 MlnJan 13 (Reuters) - Telix Pharmaceuticals Ltd TLX.AX:Q4 2024 UNAUDITED REVENUE OF US$142 MILLION, UP 46%Further company coverage: TLX.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250113:nFWN3O61NJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLX.AU"],"gpt_icon":0},{"id":"2503325653","title":"Telix Exceeds FY24 Guidance With US$142M Q4 Revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2503325653","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503325653?lang=en_us&edition=fundamental","pubTime":"2025-01-13 15:08","pubTimestamp":1736752110,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250113:nTUA7DGVTH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TLX.AU","BK7067"],"gpt_icon":0},{"id":"2503251873","title":"Press Release: Telix Exceeds FY24 Guidance with US$142M Q4 Revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2503251873","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503251873?lang=en_us&edition=fundamental","pubTime":"2025-01-13 15:08","pubTimestamp":1736752080,"startTime":"0","endTime":"0","summary":"MELBOURNE, Australia and INDIANAPOLIS, Jan. 13, 2025  -- Telix Pharmaceuticals Limited  today provides an update on its commercial and operational performance for the quarter ended 31 December 2024 .-- Q4 2024 unaudited revenue of approximately US$142 million (AU$218. million)1, represents an increase of 46% over the prior year. quarter-over-quarter increase of 5% (Q3 2024: US$135 million or AU$201. -- Telix's revenue is currently generated predominantly from sales of. -- Total FY2024 unaudited revenue is approximately US$517 million (AU$783. million) exceeding previously stated guidance of US$490 million to US$510. -- The Company intends to provide FY2025 guidance when it reports audited. for Telix's lead clinical therapeutic asset with first interim read out. U.S. Food and Drug Administration  in Q4 2024, to discuss a proposed. During Q4 2024, the Company held a pre-IND meeting with the FDA to. discuss the design of a pivotal trial for TLX101. Based on positive","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLX.AU"],"gpt_icon":0},{"id":"2503409373","title":"Telix Pharmaceuticals Ltd - Q4 2024 Unaudited Revenue of US$142 Mln, up 46%","url":"https://stock-news.laohu8.com/highlight/detail?id=2503409373","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503409373?lang=en_us&edition=fundamental","pubTime":"2025-01-13 14:11","pubTimestamp":1736748690,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250113:nFWN3O61NJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TLX.AU","BK7067"],"gpt_icon":0},{"id":"2503334866","title":"ASX Market Update: Bourse falls as Bain Capital ups the ante in fight for Insignia Financial | January 13, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2503334866","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503334866?lang=en_us&edition=fundamental","pubTime":"2025-01-13 10:10","pubTimestamp":1736734200,"startTime":"0","endTime":"0","summary":"The Aussie market has kicked off the week lower after an unexpected jump in new U.S. jobs jettisoned any near-term hopes of a rate cut by the Fed Reserve.Back home, jobs ads rose by just 0.3%, having a negligible impact on the bourse.TheAustralian dollar has extended its losing streak against the US Dollar for the fourth straight day, with the Aussie battler hovering near two-year lows at around 61.6 cents.IT has been leading the market down, giving up 2%, followed by Financials, down 1.6%, and Health Care 1.4%. Energy has been bucking the trend and is the best performing sector, up 2%, followed by Utilities, up 0.6%.Insignia Financialhas been up 2.4% after Bain Capital increased its takeover offer. Bain has offered $4.30 per share; a 7% increase on its December offer that now matches the competing bid from CC Capital Partners.Nova Mineralshas been up 1.3% after unveiling new drill-ready zones rich in gold and antimony at its Stibium prospect in Alaska. Assays from soil and rock chip s","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/asx-market-update-bourse-falls-as-bain-capital-up-the-ante-in-fight-for-insignia-financial-january-13-2025-2025-01-13/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BK7095","IFL.AU","BK7062","NVA.AU","BK7067","TLX.AU"],"gpt_icon":0},{"id":"2503311581","title":"BRIEF-Telix Pharmaceuticals To Acquire Next-Gen Therapeutics And Biologics Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2503311581","media":"Reuters","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503311581?lang=en_us&edition=fundamental","pubTime":"2025-01-13 09:24","pubTimestamp":1736731461,"startTime":"0","endTime":"0","summary":"Jan 13 (Reuters) - Telix Pharmaceuticals Ltd   :   * TLX TO ACQUIRE NEXT-GEN THERAPEUTICS AND BIOLOGICS PLATFORM   * PURCHASE PRICE FOR TRANSACTION IS US$45 MILLION Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLX.AU","BK7067"],"gpt_icon":0},{"id":"2503318252","title":"Telix to Acquire ImaginAb's Drug Candidate Pipeline, Biologics Technology Platform for $45 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2503318252","media":"MT Newswires Live","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503318252?lang=en_us&edition=fundamental","pubTime":"2025-01-13 07:41","pubTimestamp":1736725302,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals (ASX:TLX) agreed to acquire ImaginAb's pipeline of drug candidates, a proprietary biologics technology platform, and a protein engineering and radiopharmaceutical research facili","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TLX.AU","BK7067"],"gpt_icon":0},{"id":"2503259314","title":"Up 120% in a year, ASX 200 healthcare stock dips on US acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2503259314","media":"MotleyFool","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503259314?lang=en_us&edition=fundamental","pubTime":"2025-01-13 07:32","pubTimestamp":1736724735,"startTime":"0","endTime":"0","summary":"S&P/ASX 200 Index(ASX: XJO) healthcare stock Telix Pharmaceuticals Ltd (ASX: TLX) is slipping today. Shares in the diagnostic and therapeutic product developer closed on Friday trading for $23.99. In ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/01/13/up-120-in-a-year-asx-200-healthcare-stock-dips-on-us-acquisition/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["XJO.AU","BK7067","TLX.AU"],"gpt_icon":0},{"id":"2503970903","title":"Telix to Acquire Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2503970903","media":"THOMSON REUTERS","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503970903?lang=en_us&edition=fundamental","pubTime":"2025-01-13 06:49","pubTimestamp":1736722172,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250112:nTUA2RZF7P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","TLX.AU"],"gpt_icon":0},{"id":"2503390676","title":"Telix takes on ‘next-gen’ cancer drug candidates through $372m asset buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2503390676","media":"The Market Herald","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503390676?lang=en_us&edition=fundamental","pubTime":"2025-01-13 06:38","pubTimestamp":1736721480,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals Ltd  is adding to its portfolio of early-stage drug candidates, in addition to a suite of other assets, through a $73 million asset buy agreement with antibody engineering company ImaginAb, Inc.A further $299 million will also be due  once Telix hits specific key development and commercial milestones after the deal is struck.The purchased drug candidates can be described as ‘next generation,’ including some targeting surface-cell proteins such as DLL3, which is overexpressed in high-grade neuroendocrine tumors and small-cell lung cancer, and integrin αvβ6, which is overexpressed during wound healing and in cancer.With many of these target issues at early discovery stage, Telix’s ability to carry on its focus on expanding into future therapy areas to meet critical needs.Additionally, these candidates also utilise small-engineered antibody formats that allow for highly specific cancer targeting, together with fast tumor uptake and blood clearance.The material provid","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/telix-takes-on-next-gen-cancer-drug-candidates-through-372m-asset-buy-2025-01-13/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["TLX.AU","BK7067"],"gpt_icon":0},{"id":"2503940463","title":"Telix Pharmaceuticals Ltd - Tlx to Acquire Next-Gen Therapeutics and Biologics Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2503940463","media":"THOMSON REUTERS","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503940463?lang=en_us&edition=fundamental","pubTime":"2025-01-13 05:25","pubTimestamp":1736717115,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250112:nFWN3O61KK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TLX.AU","BK7067"],"gpt_icon":0},{"id":"2503394010","title":"Telix Pharmaceuticals Ltd - Purchase Price for Transaction Is US$45 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2503394010","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503394010?lang=en_us&edition=fundamental","pubTime":"2025-01-13 05:25","pubTimestamp":1736717115,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250112:nFWN3O61KK:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TLX.AU","BK7067"],"gpt_icon":0},{"id":"2502878743","title":"Here's how the ASX 200 market sectors stacked up last week","url":"https://stock-news.laohu8.com/highlight/detail?id=2502878743","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502878743?lang=en_us&edition=fundamental","pubTime":"2025-01-12 05:00","pubTimestamp":1736629200,"startTime":"0","endTime":"0","summary":"ASX200 healthcareshares led themarket sectorswith a 1.15% increase over the five trading days. The S&P/ASX 200 Index(ASX: XJO) gained 0.53% over the week to finish at 8,294.1 points on Friday. Seven o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/01/12/heres-how-the-asx-200-market-sectors-stacked-up-last-week-22/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["SIG.AU","TLX.AU","MSB.AU","BK7067","FPH.AU","BK7511","CU6.AU","COH.AU","BK7501","BK7103","RHC.AU","BK7096","PME.AU","BK7508","RMD.AU","CSL.AU","BK7007","XJO.AU","BK7124","SHL.AU","BK7094","BK7113"],"gpt_icon":0},{"id":"2502088116","title":"16 ASX shares that doubled in value last year","url":"https://stock-news.laohu8.com/highlight/detail?id=2502088116","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502088116?lang=en_us&edition=fundamental","pubTime":"2025-01-09 04:00","pubTimestamp":1736366400,"startTime":"0","endTime":"0","summary":"S&P/ASX All Ordinaries Index (ASX: XAO) shares rose by 7.55% last year and delivered total gross returns, including dividends, of 11.44%. The index closed the year at 8,420.5 points.  In comparison, t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/01/09/16-asx-shares-that-doubled-in-value-last-year/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["360.AU","BK7062","PME.AU","BK7103","BK7501","BK7061","BK7094","BK7503","ZIP.AU","BK7084","XAO.AU","BK7016","BK7067","BK7116","TNE.AU","SLC.AU","BK7093","LIF","TLX.AU","BK7096","CAT.AU","PNI.AU","CU6.AU","IPX.AU","NXL.AU","BK7104","SIG.AU","BK7508","BK4023","APX.AU","XJO.AU","BK7015","MSB.AU","SPR.AU","OBM.AU"],"gpt_icon":0},{"id":"2502776702","title":"Shares vs. property: Which investment delivered the best capital growth in 2024?","url":"https://stock-news.laohu8.com/highlight/detail?id=2502776702","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502776702?lang=en_us&edition=fundamental","pubTime":"2025-01-09 03:00","pubTimestamp":1736362800,"startTime":"0","endTime":"0","summary":"Let's look back and see which ASX shares vs. property markets delivered the best capital gains in 2024.  Shall we start with stocks?","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/01/09/shares-vs-property-which-investment-delivered-the-best-capital-growth-in-2024/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7503","BK7103","TNE.AU","CU6.AU","360.AU","SIG.AU","XJO.AU","BK7084","BK7096","CDA.AU","BK7067","BK7054","TLX.AU","XKO.AU","BK7093","XAO.AU","PNI.AU","BK7062","BK7016","ZIP.AU","HUB.AU","PME.AU","BK7094"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":10,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TLX.AU\",params:#limit:5,,,undefined,":[{"date":"2025-02-19","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1739919600000,"name":null,"time":"","dateTimestamp":1739883600000,"actualEps":null},{"date":"2024-08-22","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1724284800000,"name":null,"time":"","dateTimestamp":1724248800000,"actualEps":null},{"date":"2024-02-22","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1708556400000,"name":null,"time":"","dateTimestamp":1708520400000,"actualEps":null},{"date":"2023-10-18","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1697583600000,"name":null,"time":"","dateTimestamp":1697547600000,"actualEps":null},{"date":"2023-08-23","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1692748800000,"name":null,"time":"","dateTimestamp":1692712800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TLX.AU\",market:\"AU\",,,undefined,":[]}}